Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy - 2More parents refusing this shot that prevents serious bleeding at birth
- 3Carrying on with a Sans plastic Way of life: Individual Examinations in Maintainability
- 4Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- 5Exploring the Main Year of Life as a parent: Individual Encounters
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
- Investigate These Retreats Well known With Seniors
- Two more UN peacekeepers killed in southern Lebanon: UNIFIL
- German police 'cleared path for fascists with batons,' protesters say
- Five held on suspicion of planning attack on German Christmas market
- The Way to Business: Startup Illustrations Learned
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.'
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
